Skip to main content

Table 1 Phosphatidylinositol 3-kinase pathway alterations in human breast cancers by molecular subtype

From: Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

   

Frequency

 

Gene (protein)

Alteration

Effect on signaling

Luminal (ER+)

HER2+

Basal (TN)

Reference

ErbB2 (HER2)

Amplification or overexpression

Hyperactivation of ErbB2 signaling (PI3K, MEK)

10%

~100%

0%

[30–32]

PTEN

Loss-of-function mutation or reduced expression

Hyperactivation of PI3K signaling

29-44%

22%

67%

[6, 8, 104, 105]

PIK3CA (p110α/PI3K)

Activating mutation

Hyperactivation of PI3K signaling

28-47%

23-33%

8-25%

[6, 52, 66–68, 105–107]

PIK3CB (p110β/PI3K)

Amplification

Unknown

 

5% of all cases

 

[62]

IGF1R and INSR (IGF-1R, InsR)

Receptor activation, IGF1R amplification

Activates IGF-IR/InsR signaling (PI3K, MEK)

41-48%

18-64%

42%

[108, 109]

FGFR1

Amplification, activating mutation

Hyperactivation of FGFR signaling (PI3K, MEK)

8.6-11.6%

5.4%

5.6%

[63, 110]

RPS6K1 (p70S6K)

Amplification

Unknown

 

3.8-12.5% of all cases

 

[111]

INPP4B

Reduced expression or genomic loss

Hyperactivation of PI3K signaling

10-33%

54%

53%

[64, 112]

PIK3R1 (p85α/PI3K)

Inactivating mutation

Derepression of catalytic activity of p110α

 

2% of all cases

 

[113]

AKT1

Activating mutation

Hyperactivation of AKT

2.6-3.8%

0%

0%

[65, 66, 106, 114]

AKT2

Amplification

Hyperactivation of AKT

 

2.8% of all cases

 

[115]

EGFR

Amplification

Hyperactivation of EGFR signaling (PI3K, MEK)

 

0.8% of all cases

 

[116]

PDK1

Amplification or overexpression

Hyperactivation of PDK1 (AKT, TORC1)

22%

22%

38%

[117]

KRAS

Activating mutation

Hyperactivation of PI3K and MEK

 

4-6% of all cases

 

[118, 119]

  1. EGFR, epidermal growth factor receptor; ER, estrogen receptor; FGFR, fibroblast growth factor receptor; HER, human epidermal growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; INPP4B, inositol polyphosphate-4-phosphatase, type II; InsR, insulin receptor; MEK, mitogen-activated protein kinase kinase; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; TN, triple negative.